Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

PDF  |  How to cite

Oncotarget. 2022; 13:1306-1306. https://doi.org/10.18632/oncotarget.28318

Metrics: PDF 239 views  |   ?  

Connor Willis1, Hillevi Bauer1, Trang H. Au1, Jyothi Menon1, Sudhir Unni1, Dao Tran2, Zachary Rivers2, Wallace Akerley3, Matthew B. Schabath4, Firas Badin5, Ashley Sekhon6, Malini Patel7, Bing Xia8, Beth Gustafson9, John L. Villano10, John-Michael Thomas11, Solomon J. Lubinga12, Michael A. Cantrell13, Diana Brixner1 and David Stenehjem1,2

1Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
2Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, USA
3Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
4Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
5Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY, USA
6Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH, USA
7Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
8Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
9Precision Oncology Program, Saint Luke’s Cancer Institute, Kansas City, MO, USA
10Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA
11US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA
12Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
13Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA

Published: December 06, 2022

Copyright: © 2022 Willis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: This study proceeded with institutional IRB approvals at each participating cancer center. Due to the retrospective nature of this project, a waiver of informed consent was approved by each of the listed local IRBs.

Original article: Oncotarget. 2022; 13:257–270. DOI: https://doi.org/10.18632/oncotarget.28178

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28318